The FDA granted an expected, though long-awaited, approval to the COVID-19 vaccine. Also, Korean regulators have begun a review of Russian vaccine CoviVac, while Bavarian Nordic has initiated a Phase II study of its vaccine booster candidate and received a commitment for up to DKK 800m from the Danish government.
The US Food and Drug Administration’s full approval of Pfizer Inc./BioNTech SE’s COVID-19 vaccine BNT162b2, now Comirnaty, has expanded the companies’ options for marketing it.
As expected, the FDA granted approval for Comirnaty, the brand name that the companies have used in Europe for months,...